JanOne (NASDAQ:JAN) and Galmed Pharmaceuticals (NASDAQ:GLMD) Head-To-Head Analysis

JanOne (NASDAQ:JANGet Free Report) and Galmed Pharmaceuticals (NASDAQ:GLMDGet Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Volatility and Risk

JanOne has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Institutional and Insider Ownership

6.3% of JanOne shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 3.0% of JanOne shares are held by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares JanOne and Galmed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
JanOne N/A -177.90% -55.98%
Galmed Pharmaceuticals N/A -53.29% -44.35%

Valuation & Earnings

This table compares JanOne and Galmed Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
JanOne $39.61 million 0.80 -$7.81 million N/A N/A
Galmed Pharmaceuticals N/A N/A -$6.91 million ($3.26) -0.12

Galmed Pharmaceuticals has lower revenue, but higher earnings than JanOne.

Analyst Recommendations

This is a summary of current recommendations for JanOne and Galmed Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
JanOne 0 0 0 0 N/A
Galmed Pharmaceuticals 0 0 1 0 3.00


Galmed Pharmaceuticals beats JanOne on 6 of the 8 factors compared between the two stocks.

About JanOne

(Get Free Report)

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

About Galmed Pharmaceuticals

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Receive News & Ratings for JanOne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JanOne and related companies with MarketBeat.com's FREE daily email newsletter.